BeStock  
Stocks › Biotechnology › BMRN

Biomarin Pharmaceutical BMRN

US equityMarket cap rank #1288Biotechnology
$60.41 −$1.01 (-1.64%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $60.02 -0.65%
Open$61.53
Prev close$61.42
Day range$59.84 – $62.01
Volume6.06M
Market cap$11.70B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-572.3x
CheapRich

Near the bottom of its 5-year range · 0th percentile, 5-year average 144.9x

#2857 of 2994 stocks by PE (1 = cheapest)

Price / book1.8x
CheapRich

Near the bottom of its 5-year range · 13th percentile, 5-year average 2.9x

#2825 of 5331 stocks by PB (1 = cheapest)

Price / sales3.0x
CheapRich

Near the bottom of its 5-year range · 1st percentile, 5-year average 6.1x

#3179 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-719x-164x391x946xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$90.00
Price vs. fair value-32.9%Trading below the estimate
Star rating★★★★☆
Economic moatNarrow
UncertaintyHigh
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 1.77 – 2.88 13% (cheaper than usual) #2825 of 5331 (1 = cheapest)
PE -572.30 15.92 144.93 0% (cheaper than usual) #2857 of 2994 (1 = cheapest)
PS 3.03 2.55 6.13 1% (cheaper than usual) #3179 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on BMRN.

Sign in to join the discussion.

Scroll to Top